Mitral valve articles

MitraClip frecuencia ritmo cardíaco

Can We Treat Severe Residual Mitral Regurgitation after MitraClip without Surgery?

Can We Treat Severe Residual Mitral Regurgitation after MitraClip without Surgery?

Courtesy of Dr. Carlos Fava. Edge to edge with MitraClip was shown effective and safe, and its outcomes have been improving over these past few years. However, one of its greatest challenges involves not being able to reduce mitral regurgitation (MR) after device implantation, resulting in the need for surgery, as some studies have shown

Infarto agudo de miocardio y lesiones de múltiples niveles

New Promising Alternatives for Mitral Regurgitation

PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with grade 3+ or 4+, regardless etiology. Regurgitation grade was significantly reduced, and this was accompanied by clinical improvement in functional class, exercise capacity and quality of life. This study soon to be published in J Am Coll Cardiol

EuroPCR 2019 | COAPT: la reducción de la insuficiencia mitral está asociada a menos hospitalizaciones y muerte

EuroPCR 2019 | COAPT: Mitral Valve Reduction is Associated to Lower Hospitalization and Death

This new analysis shows the mechanism behind the benefit of using MitraClip and the necessary degree of residual mitral regurgitation (MR) to have an impact. Regardless the intervention type, patients with cardiac failure and secondary mitral regurgitation present lower hospitalization for cardiac failure, all-cause mortality and improved quality of life the lower the MR. MitraClip

MitraClip in the “Real World”

Courtesy of Dr. Carlos Fava. Mitral regurgitation (MR) is the most frequent valvulopathy in Europe and US, affecting close to 10% of patients over 75, with more morbidity and mortality. The treatment of choice is percutaneous repair instead of replacement, to maintain the sub-valvular apparatus that contributes to systole. This is feasible and has better

TAVI en bajo riesgo con “cero” mortalidad y “cero” stroke

The Significance of Aetiology on Mitral Regurgitation

Courtesy of Dr. Carlos Fava. The aetiology of mitral regurgitation (MR) may be divided into primary, organic or degenerative MR, and secondary or functional MR. These two present different physiopathology. The treatment strategy is different for each, and edge-to-edge treatment with Mitraclip is currently emerging as a valid alternative for high-risk patients. This study analyzed 943 patients

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Is Tricuspid Regurgitation after TAVR Significant?

Courtesy of Dr. Carlos Fava. Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution. A meta-analysis of 12 studies with a total 41485 patients was carried out.  

Mitral Valve Repair with MirtaClip Was Feasible and Safe

Transcatheter mitral valve repair (TMVR) with MitraClip was shown feasible and safe, and therefore a viable option for symptomatic patients with severe mitral valve regurgitation of prohibitive risk. In this regard, the procedure alleviates symptoms, cardiac regurgitation and has a potential benefit on ventricular remodeling. However, many patients presented atrial fibrillation (AF) and mitral valve

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Good Outcomes for MitraClip “Off Label”

Courtesy of Dr. Carlos Fava. Mitral regurgitation is the most frequent type of valve disease, accounting for >6% of patients over 65 years old. Surgery is currently the strategy of choice, but percutaneous treatment is a valid alternative.   The long-term progress of symptomatic patients at high surgical risk who do not meet the formal indications for

MitraClip: ¿debemos intervenir antes a nuestros pacientes?

Continuous Monitoring of Left Atrial Pressure during MitraClip, Regardless Echocardiography

The aim of this study was to assess the use of measuring left atrial pressure to complement transesophageal echocardiography and doppler imaging. Procedure efficacy is measured in the cath lab by echocardiography. However, these measurements are operator dependent and might be influenced by left ventricular function and changes in left atrial compliance.   The study

TCT 2018 | COAPT: MitraClip en pacientes con insuficiencia mitral secundaria

TCT 2018 | COAPT: MitraClip in Patients with Secondary Mitral Regurgitation

The prognosis of patients with heart failure and mitral regurgitation secondary to ventricular dysfunction and dilation is guarded. Percutaneous mitral valve treatment of these patients may at least improve their symptoms. This study was conducted in 78 sites in the United States and Canada, and included patients with moderate-to-severe (3+) or severe (4+) mitral regurgitation who

TCT 2018 | REDUCE-FMR: Anuloplastia indirecta en insuficiencia mitral secundaria

TCT 2018 | REDUCE-FMR: Indirect Annuloplasty in Secondary Mitral Regurgitation

Prior studies such as the AMADEUS, TITAN or TITAN II have shown reduction of mitral valve regurgitation (MR) with the Carillon device. This sham-controlled randomized study tested the efficacy of this device in secondary mitral regurgitation. Primary end point was echocardiographic MR reduction (blind core lab) and secondary end point were hospitalization for cardiac failure,